Figure 1.

Results: A total of 844 literature items were obtained. After screening of title, abstract and keywords we excluded 106 records as they were not emphasized the rheumatological perspective on COVID-19 and as a result were inapplicable for this study. The 738 retrieved articles were mostly (86.8%) open access publications. The top five journals that contributed most to the coverage of this topic were: *Annals Of The Rheumatic Diseases* (n=59), *Clinical Rheumatology* (n=41), *Lancet Rheumatology* (n=24), *Arthritis And Rheumatology* (n=20) and *Rheumatology International* (n=19). The origin of most studies was not surprisingly from those countries, which belong to the top ten according to the total cases of COVID-19 [1] (USA – 167; Italy – 148; UK – 76; India – 60 and Spain – 58). Most items were written in English but articles in German (n=12), Spanish (n=11), Russian (n=5) and Chinese (n=2) could also be found. Analyzed studies were designed in the form of Original Articles (41.2%), Reviews (23.7%), Letters (21.8), Notes (6.9%), Editorials (5.1%). According to the citations scores, articles of highest interest were dedicated to clinical course of COVID-19 in patients with autoimmune pathologies. The other highly cited studies were about cytokine storm and perspective usage of biological drugs for severe cases of COVID-19. Our analysis of keywords showed that the most widely discussed rheumatic disease in the view of COVID-19 was systemic lupus erythematosus (n=188), followed by vasculitis (n=132), rheumatoid arthritis (n=90), systemic sclerosis (n=32) and psoriatic arthritis (24). The liveliest discussion about disease-modifying antirheumatic drugs in COVID-19 revolved around hydroxychloroquine (n=305), corticosteroids (n=161), tocilizumab (n=83), methotrexate (n=46) and anakinra (n=34).

Conclusion: As far as we know, it is the first bibliometric overview of studies dedicated to interrelation between COVID-19 and rheumatic pathology. The high number of open access items contributes to the increase of research visibility in this emergently developing research field and facilitates the process of scientific data sharing. The conducting of bibliographic studies may provide a valuable guide through this area of knowledge.

REFERENCES:

[1] <https://www.worldometers.info/coronavirus/> Accessed on January 12, 2021

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.734

POS1173

A SHORT DELAY IN ARTHRITIS CARE IS ASSOCIATED WITH HIGHER DISEASE ACTIVITY - LESSONS FROM THE CORONAVIRUS DISEASE 19 (COVID-19) PANDEMIC

A. Giollo¹, E. Bertoldo¹, C. Benini¹, O. Viapiana¹, L. Idolazzi¹, G. Adami¹, A. Fassio¹, D. Gatti¹, M. Rossini¹. ¹University of Verona, Rheumatology Section, Department of Medicine, Verona, Italy

Background: Although disease activity is a significant outcome in rheumatology, few studies have investigated the relationship between routine care of rheumatic conditions and disease activity control.

Objectives: To determine the association between delay in routine care of chronic inflammatory arthritides (CIAs) and disease activity during the first wave of coronavirus disease 19 pandemic in Verona, Italy.

Methods: This study enrolled patients with an established diagnosis of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and undifferentiated arthritis (UA). Between 01/04/2020 and 30/06/2020, participants were emailed an online questionnaire. Items comprised multiple or single-choice questions evaluating routine rheumatology care disruptions/delays and disease characteristics, treatments, comorbidities, and demographics. Compliance to anti-rheumatic medications was evaluated with I-CQR5. Disease activity was

assessed with RAPID3, and active disease was defined as a RAPID3 score >1. Study period referred to the time between the last rheumatology assessment and the date of enrolment.

Results: Of 1210 patients contacted, 450 participated, of whom 219 CIAs patients were included (RA 55.3%, PsA 35.2%, AS 15.1%, UA 3.7%). One hundred twenty-five patients (57.1%) had their routine clinical assessment delayed (median days 68.4; IQR 66.8, 85.9). Patients in this group had significantly higher MDHAQ (p=0.001) and RAPID3 (p=0.031) scores, while they did not differ for disease severity, medications or compliance. Most (87.7%) reported good compliance to therapy; only 5.9% had difficulties in supplying anti-rheumatic medications, and 13.2% discontinued medications for at least four weeks for any reason. However, several patients (37.9%) reported moderate-to-high worse disease activity perception due to routine care delay, and 31.1% self-reported a disease flare (median RAPID3 score 3.8; IQR 2.0, 5.4). One hundred one patients (46.1%) had high disease activity, while only 15.1% were in remission. In logistic regression, active disease was significantly associated with delay of scheduled routine care visit, independent of disease duration, time from last rheumatology assessment, therapy with b/tsDMARDs, and compliance (Table 1, Figure 1 below).

Table 1.

Predictor	Active (n=186)	Remission (n=33)	OR	P-value	95% CI Inf.	95% CI Sup.
Routine care delay (yes vs no)	113 (60.8%)	12 (36.4%)	.030	2.459	1.091	5.543
Disease duration (years)	10 (4.0, 20.0)	10.5 (7.0, 19.8)	.695	1.007	.972	1.044
Time since last rheumatology assessment (days)	68.4 (66.8, 75.8)	71.2 (66.9, 74.9)	.854	1.002	.978	1.027
b/tsDMARDs (yes vs no)	105 (56.5%)	15 (45.5%)	.653	1.202	.538	2.687
I-CPR5 (likely low vs likely high adherent)	36 (19.4%)	10 (30.3%)	.187	.563	.240	1.321

Figure 1.

Conclusion: In patients with established CIAs, a relatively short delay in routine assessment by a rheumatologist resulted in higher disease activity. Frequent rheumatology referrals appear to be a critical factor for disease activity control in CIAs.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.737

POS1174

HYPERINFLAMMATION AND CLINICAL OUTCOMES FOR PATIENTS WITH SYSTEMIC RHEUMATIC DISEASES HOSPITALIZED FOR COVID-19: A COMPARATIVE COHORT STUDY

T. Hsu^{1,2}, K. D'silva^{2,3}, N. Serling-Boyd^{2,3}, J. Wang¹, A. Mueller^{1,2}, X. Fu³, L. Prisco¹, L. Martin¹, K. Vanni¹, A. Zaccardelli¹, C. Cook³, H. Choi^{2,3}, Y. Zhang^{2,3}, E. Gravallese^{1,2}, Z. Wallace^{2,3}, J. Sparks^{1,2}. ¹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, United States of America; ²Harvard Medical School, Division of Rheumatology, Inflammation, and Immunity, Boston, United States of America; ³Massachusetts General Hospital, Division of Rheumatology, Allergy, and Immunology, Boston, United States of America